Dendritic cell-based vaccines in patients with hematological malignancies

Annals of the New York Academy of Sciences

Volumn 938, Issue , 2001, Pages 359-363

  Brugger, Wolfram ^a   Schneider, Anya ^a   Schammann, Theodora ^a   Dill, Patricia ^a   Grünebach, Frank ^a   Bühring, Hans Jörg ^a   Kanz, Lothar ^a   Brossart, Peter ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

AML; Dendritic cells; Immunotherapy; Leukemia; MUC1; T cell epitopes

Indexed keywords

DENDRITIC CELL VACCINE; HLA A2 ANTIGEN; MUCIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN PRESENTING CELL; ASSAY; CONFERENCE PAPER; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HEMATOLOGIC DISEASE; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; LEUKEMIA;

EID: 0034942530     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb03603.x     Document Type: Conference Paper

References (9)

1. Advances in immunotherapy of hematologic malignancies: Cellular and humoral approaches
2. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units
3. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
4. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide
5. Defining the carcinogen activator cytochrome P450 1B1 as a universal tumor antigen for lymphoma and leukemia
6. MUC1 is activated in a B-cell lymphoma by the t(1;14) (q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets
7. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies
8. Induction of CTL responses in vivo after vaccinations with peptide pulsed dendritic cells
9. Expression of MUC-1 epitopes in normal bone marrow: Implications for the detection of micrometastatic tumor cells